267 related articles for article (PubMed ID: 13679646)
1. Biochemistry and clinical pharmacology of new anticoagulant agents.
Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
[TBL] [Abstract][Full Text] [Related]
2. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
4. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
Samama MM; Gerotziafas GT
Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
[TBL] [Abstract][Full Text] [Related]
6. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Ieko M; Tarumi T; Nakabayashi T; Yoshida M; Naito S; Koike T
Front Biosci; 2006 Jan; 11():232-48. PubMed ID: 16146728
[TBL] [Abstract][Full Text] [Related]
7. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
8. [New anticoagulants].
Levi M; Peters RJ; Piek JJ; Büller HR
Ned Tijdschr Geneeskd; 2003 May; 147(19):909-15. PubMed ID: 12768805
[TBL] [Abstract][Full Text] [Related]
9. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
Andersen JC
Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
11. Management of thrombotic and cardiovascular disorders in the new millenium.
Fareed J; Hoppensteadt DA; Bick RL
Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
[TBL] [Abstract][Full Text] [Related]
12. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
Leone G; Rossi E; Leone AM; De Stefano V
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):311-26. PubMed ID: 15320782
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
14. Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
Walenga JM; Fareed J; Jeske WP; Bıck RL; Samama MM
Turk J Haematol; 2002 Jun; 19(2):137-50. PubMed ID: 27264755
[TBL] [Abstract][Full Text] [Related]
15. New anticoagulants: anti IIa vs anti Xa--is one better?
Bauer KA
J Thromb Thrombolysis; 2006 Feb; 21(1):67-72. PubMed ID: 16475045
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of synthetic factor Xa inhibitors.
Gerotziafas GT; Samama MM
Curr Pharm Des; 2005; 11(30):3855-76. PubMed ID: 16305517
[TBL] [Abstract][Full Text] [Related]
17. New anticoagulants.
Bauer KA
Hematology Am Soc Hematol Educ Program; 2006; ():450-6. PubMed ID: 17124098
[TBL] [Abstract][Full Text] [Related]
18. New trends in anticoagulant therapy.
Pengo V; Pegoraro C; Iliceto S
Isr Med Assoc J; 2004 Aug; 6(8):479-81. PubMed ID: 15326828
[TBL] [Abstract][Full Text] [Related]
19. Fondaparinux (Arixtra): a new anticoagulant.
Giangrande PL
Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
[TBL] [Abstract][Full Text] [Related]
20. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
